Summary
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.
History
Athenex was founded in 2002 with a mission of identifying and developing novel, small-molecule therapies for the treatment of cancer. Since then, the company has grown from a two-person start-up to a publicly-traded global pharmaceutical company with more than 400 employees and operations in the United States, China, United Kingdom, and Australia.
Mission
Our mission is to develop innovative therapies to improve and extend the lives of people living with cancer.
Vision
Our vision is to become a leader in the development of novel, small molecule therapies for the treatment of cancer.
Key Team
Caileigh Dougherty (Director of Investor Relations)
Dr. Rudolf Kwan B.S., M.B., M.D., MBBS (Chief Medical Officer)
Ms. Jacqueline Li (VP of Alliance Management & Corp. Devel.)
Dr. Daniel Lang M.D. (Pres of Athenex Cell Therapy)
Mr. John W. Matthei (Chief Human Resource Officer)
Dr. Allen Barnett (Co-Founder & Pres Emeritus)
Mr. Joe Annoni C.F.A. (Chief Financial Officer)
Recognition and Awards
Athenex has achieved numerous awards, including “Best Specialty Pharmaceutical Company of the Year” by Scrip Awards in 2020, “Best Clinical Trial Support Company” by Scrip Awards in 2019, and “Biotechnology Innovator” by the Wall Street Journal in 2017.
References
United States 